Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML-NK cells for relapsed or refractory AML
NCT05580601Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- May 2023
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), sponsored by Cincinnati Children's Hospital Medical Center. Started May 2023; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05580601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580601.